share_log

bluebird bio | 10-Q: Q1 2024 Earnings Report

SEC ·  Sep 13, 2024 20:42

Summary by Futu AI

bluebird bio reported Q1 2024 total revenue of $18.6 million, up from $2.4 million in Q1 2023, driven primarily by ZYNTEGLO product sales. Net loss was $69.8 million compared to net income of $18.9 million in Q1 2023. Cost of product revenue increased to $25.9 million from $5.5 million last year.Selling, general and administrative expenses rose to $46.3 million from $37.5 million, mainly due to increased headcount and professional fees. Research and development expenses decreased to $25.1 million from $41.6 million, reflecting lower manufacturing costs as commercial production is now included in inventory and cost of goods sold.The company ended the quarter with $212.0 million in cash and cash equivalents. In March 2024, bluebird secured a $175 million term loan facility with Hercules Capital, with $75 million drawn at closing. Management expects current cash to fund operations into Q1 2025, though substantial doubt exists regarding the company's ability to continue as a going concern without additional funding.
bluebird bio reported Q1 2024 total revenue of $18.6 million, up from $2.4 million in Q1 2023, driven primarily by ZYNTEGLO product sales. Net loss was $69.8 million compared to net income of $18.9 million in Q1 2023. Cost of product revenue increased to $25.9 million from $5.5 million last year.Selling, general and administrative expenses rose to $46.3 million from $37.5 million, mainly due to increased headcount and professional fees. Research and development expenses decreased to $25.1 million from $41.6 million, reflecting lower manufacturing costs as commercial production is now included in inventory and cost of goods sold.The company ended the quarter with $212.0 million in cash and cash equivalents. In March 2024, bluebird secured a $175 million term loan facility with Hercules Capital, with $75 million drawn at closing. Management expects current cash to fund operations into Q1 2025, though substantial doubt exists regarding the company's ability to continue as a going concern without additional funding.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 607

Recommended